One of the biggest hurdles in cancer treatment is the development of resistance to drugs. While initial therapies can effectively reduce tumors and slow disease progression, cancer cells often adapt over time, finding ways to survive despite ongoing treatment.
This issue is especially prevalent in advanced kidney cancer, where many patients eventually run out of effective treatment options.
Researchers at Mayo Clinic have shared promising early results from a clinical trial that may help overcome this challenge. Their study explored a new experimental drug called darlifarnib, used in combination with cabozantinib, a standard therapy for advanced clear cell renal cell carcinoma, the most common type of kidney cancer in adults.
Clear cell renal cell carcinoma accounts for the majority of kidney cancer cases. Although targeted therapies and immunotherapies have improved survival rates for many patients, the disease tends to become harder to control as resistance develops. This has driven researchers to look for treatments that can counteract the cancer’s ability to adapt.
The recent study aimed to determine if darlifarnib could boost the effects of cabozantinib. Scientists believe that darlifarnib may block critical signaling pathways that cancer cells use to grow and survive. By combining it with cabozantinib, the goal was to prevent tumors from exploiting alternative routes for growth.
This was a phase 1a/b trial, representing one of the initial tests of this drug combo in humans. Eighteen patients with advanced clear cell renal cell carcinoma participated. All had previously been treated with cabozantinib, with many having received multiple other therapies, including roughly half who had undergone three or more prior treatments.
This group faces significant unmet medical needs since treatment options tend to dwindle after several therapies fail. Discovering a treatment that remains effective in such cases would represent a substantial advancement.
Of the 16 patients evaluated, seven experienced measurable tumor reduction, resulting in a response rate of about 44%. Additionally, 94% of the assessable patients achieved disease control, meaning their tumors either shrank or remained stable.
Dr. Yousef Zakharia, the study’s lead researcher and a medical oncologist at Mayo Clinic in Arizona, described these preliminary results as encouraging. He emphasized the ongoing need for more effective treatments for advanced kidney cancer, sharing the findings at the 2026 International Kidney Cancer Symposium: Europe in Paris.
Researchers believe the combination’s effectiveness may stem from its ability to target multiple pathways that drive cancer growth. Cancer cells often survive treatments by activating backup mechanisms when one pathway is blocked. Adding darlifarnib could make it more difficult for tumors to employ these escape routes.
The significance of these early results is heightened by the fact that the patients involved had already shown disease progression despite previous treatments. The observed tumor shrinkage and disease stabilization suggest the combination might overcome some forms of resistance.
Nevertheless, experts caution interpreting early-stage data, as small studies can sometimes produce results that aren’t replicable in larger trials. The next step is to see if these benefits can be consistently achieved across a broader patient population.
Ongoing international trials will continue to evaluate this drug combo in additional patients. Future research will clarify how long responses last, whether survival improves, and which patients are most likely to benefit.
If the current positive trends persist, the combination of darlifarnib and cabozantinib could become a new treatment option for advanced kidney cancer patients who have exhausted standard therapies. Even small steps forward can have a meaningful impact for patients and their families facing this disease.
If you’re interested in cancer research, consider reading about how a low-carb diet might increase overall cancer risk and new strategies to extend the lifespan of cancer survivors.
For more health insights, explore recent studies on anti-cancer superfoods and findings indicating that daily vitamin D3 supplementation could reduce the risk of cancer death.
Source: Mayo Clinic.